Public Companies
Small Pharma Announces Additional Positive Data From Phase 2a Trial
The article Small Pharma Announces Additional Positive Data From Phase 2a Trial was originally published on Microdose.
Back in end-January, we reported…
The article Small Pharma Announces Additional Positive Data From Phase 2a Trial was originally published on Microdose.
Back in end-January, we reported on Small Pharma’s positive results for its Phase 2a trial using DMT-assisted therapy to treat Major Depressive Disorder. 3 months after a single dose of DMT — paired with preparation and integration therapy — 57% of depression patients were considered to be in remission.
These were very encouraging results, backing up the thesis that faster-acting psychedelics like DMT could provide significant healing potential in a much shorter period.
Today, both patients and investors received additional good news, as Small Pharma has reported supportive data to corroborate its initial Phase 2 trial topline results.
Analyses of additional secondary and exploratory endpoints, including effects on self-reported depression, anxiety and wellbeing, demonstrated that patients receiving at least a single dose of IV SPL026 with supportive therapy experienced clinically relevant improvements in function and mood, further supporting previously announced topline efficacy results.
Patients’ self-reported depression and well-being scores that matched previous topline MADRS efficacy data. There was also statistically significant improvement in anxiety symptoms, which could offer potential new indications for the medicine beyond depression.
See below for our chat with EF Hutton analyst about Small Pharma’s program and read the full press release below.
dmt psychedelic therapy major depressive disorder depressive disorder depression anxiety psychedelics investors small pharma
-
Law & Regulation1 week ago
Relmada Therapeutics trims losses, slashes research costs
-
Psychedelics1 week ago
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Psychedelics1 week ago
Elon Musk Continues To Defend Ketamine
-
Psychedelics1 week ago
Numinus Wellness Submits Clinical Trial Application
-
Psychedelics1 week ago
Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
-
Psychedelics1 week ago
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
-
Psilocybin6 days ago
Indigenous Psilocybin Practices Around the World
-
Psychedelics1 week ago
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas